The Molecular Pathology of Acute Myeloid Leukemia
Open Access
- 1 January 2005
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2005 (1) , 137-142
- https://doi.org/10.1182/asheducation-2005.1.137
Abstract
The pathogenesis of acute myelogenous leukemia (AML) involves an array of molecular alterations that disrupt almost every facet of cell transformation. These processes include the regulation of cell proliferation, differentiation, self-renewal, survival, cell cycle checkpoint control, DNA repair and chromatin stability, and cell dissemination. Normal regulatory networks are disrupted or usurped by these leukemogenic insults, and the understanding of these alterations is guiding the design of new therapeutic strategies. This overview describes some of the critical molecular alterations and implicates the rogue leukemogenic proteins in the onset and progression of AML.Keywords
This publication has 39 references indexed in Scilit:
- The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromesBlood, 2005
- On the molecular origins of the chronic myeloproliferative disorders: it all makes senseBlood, 2005
- Interplay of RUNX1/MTG8 and DNA Methyltransferase 1 in Acute Myeloid LeukemiaCancer Research, 2005
- After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignanciesBlood, 2005
- Prognostically Useful Gene-Expression Profiles in Acute Myeloid LeukemiaNew England Journal of Medicine, 2004
- Epigenetic consequences of AML1-ETO action at the human c-FMS locusThe EMBO Journal, 2003
- Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemiaNature Genetics, 2003
- The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressorBlood Cells, Molecules, and Diseases, 2003
- Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cellsLeukemia, 2003
- AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemiaNature Medicine, 2001